{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:28:50Z","timestamp":1784762930005,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["AR47785"],"award-info":[{"award-number":["AR47785"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00296-017-3835-x","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T07:29:19Z","timestamp":1507879759000},"page":"2071-2078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Meloxicam and risk of myocardial infarction: a population-based nested case\u2013control study"],"prefix":"10.1007","volume":"37","author":[{"given":"Deepan","family":"Dalal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhina","family":"Neogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Felson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"key":"3835_CR1","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520\u20131528. doi:\n                        10.1056\/NEJM200011233432103","journal-title":"N Engl J Med"},{"key":"3835_CR2","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092\u20131102. doi:\n                        10.1056\/NEJMoa050493","journal-title":"N Engl J Med"},{"key":"3835_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"NA Nussmeier","year":"2005","unstructured":"Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL et al (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081\u20131091. doi:\n                        10.1056\/NEJMoa050330","journal-title":"N Engl J Med"},{"key":"3835_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071\u20131080. doi:\n                        10.1056\/NEJMoa050405","journal-title":"N Engl J Med"},{"key":"3835_CR5","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","volume":"368","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368:1771\u20131781","journal-title":"Lancet"},{"key":"3835_CR6","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","volume":"115","author":"EM Antman","year":"2007","unstructured":"Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA et al (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115:1634\u20131642. doi:\n                        10.1161\/CIRCULATIONAHA.106.181424","journal-title":"Circulation"},{"key":"3835_CR7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00000542-200603000-00020","volume":"104","author":"NA Nussmeier","year":"2006","unstructured":"Nussmeier NA, Whelton AA, Brown MT, Joshi GP, Langford RM, Singla NK et al (2006) Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology 104:518\u2013526","journal-title":"Anesthesiology"},{"key":"3835_CR8","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMp048288","volume":"351","author":"GA Fitzgerald","year":"2004","unstructured":"Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:1709\u20131711. doi:\n                        10.1056\/NEJMp048288","journal-title":"N Engl J Med"},{"key":"3835_CR9","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.112.112607","volume":"126","author":"AM Olsen","year":"2012","unstructured":"Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C et al (2012) Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation 126:1955\u20131963. doi:\n                        10.1161\/CIRCULATIONAHA.112.112607","journal-title":"Circulation"},{"key":"3835_CR10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9343(98)00091-6","volume":"104","author":"B Cryer","year":"1998","unstructured":"Cryer B, Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104:413\u2013421","journal-title":"Am J Med"},{"key":"3835_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1517\/14740338.2014.907792","volume":"13","author":"F Salvo","year":"2014","unstructured":"Salvo F, Antoniazzi S, Duong M, Molimard M, Bazin F, Fourrier-Reglat A et al (2014) Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf 13:573\u2013585. doi:\n                        10.1517\/14740338.2014.907792","journal-title":"Expert Opin Drug Saf"},{"key":"3835_CR12","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086. doi:\n                        10.1136\/bmj.c7086","journal-title":"BMJ"},{"key":"3835_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pds.3437","volume":"22","author":"C Varas-Lorenzo","year":"2013","unstructured":"Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F et al (2013) Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 22:559\u2013570. doi:\n                        10.1002\/pds.3437","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3835_CR14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2165\/00003495-199651030-00007","volume":"51","author":"S Noble","year":"1996","unstructured":"Noble S, Balfour JA (1996) Meloxicam. Drugs 51:424\u2013430 (discussion 431\u2013432)","journal-title":"Drugs"},{"key":"3835_CR15","doi-asserted-by":"crossref","first-page":"s32","DOI":"10.1097\/00124743-199810001-00006","volume":"4","author":"M Distel","year":"1998","unstructured":"Distel M (1998) Meloxicam clinical data on a preferential cyclooxygenase-2 inhibitor. J Clin Rheumatol 4:s32\u2013s39","journal-title":"J Clin Rheumatol"},{"key":"3835_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2165\/11633470-000000000-00000","volume":"35","author":"J Castellsague","year":"2012","unstructured":"Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F et al (2012) Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 35:1127\u20131146. doi:\n                        10.2165\/11633470-000000000-00000","journal-title":"Drug Saf"},{"key":"3835_CR17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1063-4584(97)80024-6","volume":"5","author":"HS Goei The","year":"1997","unstructured":"Goei The HS, Lund B, Distel MR, Bluhmki E (1997) A double-blind, randomized trial to compare meloxicam 15\u00a0mg with diclofenac 100\u00a0mg in the treatment of osteoarthritis of the knee. Osteoarthr Cartil 5:283\u2013288","journal-title":"Osteoarthr Cartil"},{"issue":"Suppl 1","key":"3835_CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/rheumatology\/35.suppl_1.22","volume":"35","author":"JA Wojtulewski","year":"1996","unstructured":"Wojtulewski JA, Schattenkirchner M, Barcelo P, Le Loet X, Bevis PJ, Bluhmki E et al (1996) A 6-month double-blind trial to compare the efficacy and safety of meloxicam 7.5\u00a0mg daily and naproxen 750\u00a0mg daily in patients with rheumatoid arthritis. Br J Rheumatol 35(Suppl 1):22\u201328","journal-title":"Br J Rheumatol"},{"key":"3835_CR19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0149-2918(00)89009-8","volume":"22","author":"F Degner","year":"2000","unstructured":"Degner F, Sigmund R, Zeidler H (2000) Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther 22:400\u2013410","journal-title":"Clin Ther"},{"key":"3835_CR20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/rheumatology\/37.9.946","volume":"37","author":"J Dequeker","year":"1998","unstructured":"Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E et al (1998) Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 37:946\u2013951","journal-title":"Br J Rheumatol"},{"key":"3835_CR21","unstructured":"United States securities and exchange commission. \n                        http:\/\/www.sec.gov\/Archives\/edgar\/data\/1492426\/000119312512129945\/d272296d10k.htm\n                        \n                     \n                        http:\/\/www.sec.gov\/Archives\/edgar\/data\/1492426\/000119312512129945\/d272296d10k.htm:1-123"},{"key":"3835_CR22","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.300.6732.1092","volume":"300","author":"J Chisholm","year":"1990","unstructured":"Chisholm J (1990) The read clinical classification. BMJ 300:1092","journal-title":"BMJ"},{"key":"3835_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/pds.1335","volume":"16","author":"JD Lewis","year":"2007","unstructured":"Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL (2007) Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 16:393\u2013401. doi:\n                        10.1002\/pds.1335","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3835_CR24","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2008.08.041","volume":"52","author":"LA Garcia Rodriguez","year":"2008","unstructured":"Garcia Rodriguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52:1628\u20131636. doi:\n                        10.1016\/j.jacc.2008.08.041","journal-title":"J Am Coll Cardiol"},{"key":"3835_CR25","first-page":"85","volume":"27","author":"T Raghunathan","year":"2001","unstructured":"Raghunathan T, Lepkowski J, Van Hoewyk J, Solenberger P (2001) A Multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 27:85\u201395","journal-title":"Surv Methodol"},{"key":"3835_CR26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala N, Emberson J, Merhi A, Abramson S, Arber N et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769\u2013779. doi:\n                        10.1016\/S0140-6736(13)60900-9","journal-title":"Lancet"},{"key":"3835_CR27","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/eurheartj\/ehl053","volume":"27","author":"A Helin-Salmivaara","year":"2006","unstructured":"Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE et al (2006) NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case\u2013control study from Finland. Eur Heart J 27:1657\u20131663","journal-title":"Eur Heart J"},{"key":"3835_CR28","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1161\/01.CIR.0000132491.96623.04","volume":"109","author":"LA Garcia Rodriguez","year":"2004","unstructured":"Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A (2004) Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109:3000\u20133006. doi:\n                        10.1161\/01.CIR.0000132491.96623.04","journal-title":"Circulation"},{"key":"3835_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2796.2008.01991.x","volume":"264","author":"TP Staa van","year":"2008","unstructured":"van Staa TP, Rietbrock S, Setakis E, Leufkens HG (2008) Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 264:481\u2013492. doi:\n                        10.1111\/j.1365-2796.2008.01991.x","journal-title":"J Intern Med"},{"issue":"1","key":"3835_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2261-12-4","volume":"12","author":"WY Shau","year":"2012","unstructured":"Shau WY, Chen HC, Chen ST, Chou HW, Chang CH, Kuo CW et al (2012) Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan\u2019s National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord 12(1):4. doi:\n                        10.1186\/1471-2261-12-4","journal-title":"BMC Cardiovasc Disord"},{"key":"3835_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00002018-200629030-00009","volume":"29","author":"WF Huang","year":"2006","unstructured":"Huang WF, Hsiao FY, Tsai YW, Wen YW, Shih YT (2006) Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf 29:261\u2013272","journal-title":"Drug Saf"},{"key":"3835_CR32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-142-7-200504050-00113","volume":"142","author":"LE Levesque","year":"2005","unstructured":"Levesque LE, Brophy JM, Zhang B (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142:481\u2013489","journal-title":"Ann Intern Med"},{"key":"3835_CR33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/hrt.2006.089367","volume":"93","author":"JM Brophy","year":"2007","unstructured":"Brophy JM, Levesque LE, Zhang B (2007) The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 93:189\u2013194","journal-title":"Heart"},{"key":"3835_CR34","doi-asserted-by":"publisher","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","volume":"8","author":"P McGettigan","year":"2011","unstructured":"McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8:e1001098. doi:\n                        10.1371\/journal.pmed.1001098","journal-title":"PLoS Med"},{"key":"3835_CR35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/ard.2003.019695","volume":"64","author":"G Singh","year":"2005","unstructured":"Singh G, Mithal A, Triadafilopoulos G (2005) Both COX-2 specific inhibitors and non-specific NSAIDS increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class (abstract). Ann Rheum Dis 64:85","journal-title":"Ann Rheum Dis"},{"key":"3835_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10787-014-0225-9","volume":"23","author":"W Asghar","year":"2015","unstructured":"Asghar W, Jamali F (2015) The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 23:1\u201316. doi:\n                        10.1007\/s10787-014-0225-9","journal-title":"Inflammopharmacology"},{"issue":"Suppl 1","key":"3835_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/35.suppl_1.39","volume":"35","author":"J Hosie","year":"1996","unstructured":"Hosie J, Distel M, Bluhmki E (1996) Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 35(Suppl 1):39\u201343","journal-title":"Br J Rheumatol"},{"key":"3835_CR38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1592\/phco.20.9.741.35209","volume":"20","author":"SS Jick","year":"2000","unstructured":"Jick SS (2000) The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy 20:741\u2013744","journal-title":"Pharmacotherapy"},{"key":"3835_CR39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1365-2125.2010.03627.x","volume":"69","author":"AA Mangoni","year":"2010","unstructured":"Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM (2010) Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol 69:689\u2013700. doi:\n                        10.1111\/j.1365-2125.2010.03627.x","journal-title":"Br J Clin Pharmacol"},{"key":"3835_CR40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clinthera.2010.04.009","volume":"32","author":"JM Scheiman","year":"2010","unstructured":"Scheiman JM, Hindley CE (2010) Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 32:667\u2013677. doi:\n                        10.1016\/j.clinthera.2010.04.009","journal-title":"Clin Ther"},{"key":"3835_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/0091270004266623","volume":"44","author":"J Ryn Van","year":"2004","unstructured":"Van Ryn J, Kink-Eiband M, Kuritsch I, Feifel U, Hanft G, Wallenstein G et al (2004) Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 44:777\u2013784. doi:\n                        10.1177\/0091270004266623","journal-title":"J Clin Pharmacol"},{"key":"3835_CR42","doi-asserted-by":"publisher","first-page":"i4857","DOI":"10.1136\/bmj.i4857","volume":"354","author":"A Arfe","year":"2016","unstructured":"Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B et al (2016) Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case\u2013control study. BMJ 354:i4857. doi:\n                        10.1136\/bmj.i4857","journal-title":"BMJ"},{"key":"3835_CR43","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","volume":"26","author":"WH Shrank","year":"2011","unstructured":"Shrank WH, Patrick AR, Brookhart MA (2011) Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 26:546\u2013550. doi:\n                        10.1007\/s11606-010-1609-1","journal-title":"J Gen Intern Med"},{"key":"3835_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P (2017) Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 167:268\u2013274. doi:\n                        10.7326\/M16-2607","journal-title":"Ann Intern Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-017-3835-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3835-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3835-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T07:35:27Z","timestamp":1509953727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-017-3835-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3835"],"URL":"https:\/\/doi.org\/10.1007\/s00296-017-3835-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,13]]}}}